:: ::
Back to the articles list Back to browse issues page
BIRC5 Gene Disruption via CRISPR/Cas9n Platform Suppress Acute Myelocytic Leukemia Progression
Manizheh Narimani , Mohammadreza Sharifi , Mohammad Saeed Hakhamaneshi , Daem Roshani , Mohammad Kazemi , Seyed Hossein Hejazi , Ali Jalili *
Abstract:  
Background: Acute myelocytic leukemia (AML) is a clonal malignancy resulting from the accumulation of genetic abnormalities in the cells. Human baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), encodes survivin, is one of only a handful of genes that is differentially over-expressed in numerous malignant diseases including AML. Methods: The BIRC5 was silenced permanently in two AML cell lines, HL‑60 and KG-1, via the CRISPR/Cas9n system. After transfection of CRISPR constructs, genomic DNA was extracted and amplified to assess mutation detection. To evaluate BIRC5 gene expression, quantitative real-time PCR was performed. Also, MTT cell viability and Annexin‑V/propidium iodide flowcytometric staining were performed, and the data were analyzed using the Kolmogorov-Smirnov, Levene's, and ANOVA tests. Results: The results indicated that Cas9n and its sgRNAs successfully triggered site-specific cleavage and mutation in the BIRC5 gene locus. Moreover, suppression of BIRC5 resulted in the reduction of cell viability, and induction of apoptosis and necrosis in HL60 and KG1 suggested that the permanent suppression of BIRC5 remarkably dropped the gene expression and cells viability. Conclusion: This study reinforces the idea that BIRC5 disruption via Cas9n:sgRNAs has favorable effects on the AML clinical outcome. It thereby can be a promising candidate in a variety of leukemia treatments.
Keywords: Acute myelocytic leukemia (AML), CRISPR, Gene editing, Survivin
Full-Text [PDF 1051 kb]      
Type of Study: Full Length | Subject: Medical Biotechnology
Add your comments about this article
Your username or Email:

CAPTCHA code


XML     Print



Back to the articles list Back to browse issues page
Persian site map - English site map - Created in 0.2 seconds with 38 queries by YEKTAWEB 3879